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Abstract
Background: Serum alanine transaminase (ALT) has been used as a surrogate marker for detection of hepatitis B
and C in blood donors in Pakistan since 1985. Since the introduction of more sensitive assays the value of ALT
became questionable but it was still used with subsequent wastage of blood units with raised ALT.
Findings: We conducted a study for a period of one year to evaluate the usefulness of ALT. During the study
period, 25117 subjects donated blood. Eight hundred and seventy two donors (3.4%) were positive for one or more
serological tests. ALT of all donors ranged from 0–1501 U/L (Mean ± SD; 33.4 ± 25.45U/L). The donors seronegative
for all disease markers were 24245 (96.6%). Of these, 21164 (84.2%) donors had their ALT within reference range
while 2874 (11.4%) and 207 (0.8%) of donors had minimal and markedly elevated results respectively. Six hundred
and twenty one blood units (including red cells, platelets and plasma) were discarded based on elevated ALT
results alone at a cost of $39,123. Two hundred seronegative blood donors with normal ALT, minimally and
markedly elevated ALT levels, were selected randomly and evaluated for hepatitis B deoxynucleic acid by individual
PCR. None of the donors was found to be reactive.
Conclusion: This work did not support a positive association between hepatitis B virus nucleic acid and elevated
ALT in healthy serologically negative blood donors.
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Findings
Hepatitis B virus (HBV) infection is a major health problem with 400 million chronically infected subjects in the
world [1]. Serum alanine aminotransferase (ALT) is most
frequently used screening test in evaluation of liver damage. It has also been used historically as a surrogate marker in blood donors [2]. Previous studies have shown
that alcoholism and obesity are the most common
causes of elevated ALT in blood donors [3]. Since newer,
sensitive techniques like fourth generation ELISA became available [4], the value of using ALT as a surrogate
marker was reconsidered. The cost of ALT per sample is
$3 and the expense of discarding a single blood product
with elevated ALT is approximately $63 in our setting.
Therefore this study aimed to correlate the association
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of hepatitis B virus deoxyribonucleic acid with serum
alanine transaminase in healthy seronegative blood
donors.
We enrolled healthy non-commercial blood donors
after taking written informed consent between the ages
of 17–65 years after approval from institutional ethical
review committee of The Aga Khan University. The
study was conducted for a period of one year from November 2006 to October 2007. Five ml of blood in a gel
tube (BD vacutainer) was collected from the donated
blood bag. Tubes were centrifuged for 5 minutes at
2500 g. Separated sera were transferred to eppendorf
tubes and transported to molecular research laboratory
and samples were kept frozen at -80°C till testing which
was done in six weeks time. All donations were screened
simultaneously for anti- HIV I and II, anti HCV, HBsAg,
syphilis and malaria. Viral serology was performed via
third generation CA (Vitros Eci, Johnson and Johnson,
Ortho Clinical and Diagnostic, NY, USA) while VDRL
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Figure 1 legend: This figure shows the breakdown of 200 randomly selected seronegative healthy blood donors with markedly
elevated, minimally elevated and normal ALT levels. Hepatitis B deoxyribonucleic acid by RT-PCR was performed in all donors. None of the
donors tested positive showing no correlation with elevated ALT and occult hepatitis B infection.

(VDRL Carbon antigen Plasmatec Laboratory products RPR kit) and ICT malaria tests (Now malaria; Binax
incorporated, USA) were done manually for screening
syphilis and malaria respectively. Each donation was also
tested for serum ALT by kinetic method at a reaction
wavelength of 340 nm at a temperature of 25°C (Beckman Synchron; CX7, USA). As per institutional policy,
all blood bags which were reactive for one or more disease markers and or two times the upper limit of ALT
were incinerated. Donors were grouped into three
groups according to ALT levels: A: donors within reference range, B: minimally elevated and group C with
markedly raised levels. Reference ranges for ALT established in our lab are 3-33U/L for females and 0-55U/L
for males. Markedly elevated ALT was defined as results
greater than twice the upper limit of reference range
(≥110 U/l for males and ≥66 U/l for females). ALT
within these two limits was considered as minimal elevations (56–109 U/l for males and 34–65 U/l for females).
Within these three groups, 200 seronegative blood
donors were randomly selected (group A, n = 88, group
B, n = 12 and group C, n = 100) and tested for hepatitis B
virus deoxyribonucleic acid to exclude the possibility of
occult hepatitis B infection. These donors were seronegative for all viral markers with normal or elevated
ALT levels. The test was performed utilizing AJ
ROBOSCREEN; (Real time polymerase chain reaction)
which has an analytic sensitivity of 50 IU/ml.
During the study period, 25117 subjects donated
blood. There were 23685 (94.2%) males and 1432 (5.6%)
females with age ranging from 17 to 65 years (median ±

SD 27.7 ± 7.621). There were 872 donors (3.4%) who
had one or more abnormal screening results. A total of
n = 908 abnormal tests were detected. There were 84.2%
donors (n = 21164) who had ALT within reference range
while minimal and markedly elevated ALT were seen in
11.4% (n = 2874) and 0.8% (n = 207) subjects. Out of
n = 908 abnormal tests, donors with elevated ALT and
Hepatitis B surface antigen positivity were n = 250 (1.0%)
which were excluded from the final analysis.
Real Time Polymerase chain reaction for detection of
hepatitis B virus deoxyribonucleic acid was performed in
200 randomly selected seronegative donors from groups
A, B and C. None of the donors screened positive for
hepatitis B virus infection (Figure 1).
Blood banks all over the world have replaced ALT testing as a surrogate marker in blood donors with newer
sensitive tests [5]. We performed hepatitis B virus DNA
by RT-PCR on seronegative blood donors and none was
found to be reactive in all three groups. Since the establishment of blood bank in our laboratory which was in
the year 1985, we have been discarding blood units with
elevated ALT. With the availability of real time polymerase chain reaction we evaluated the true value of ALT
testing in identifying hepatitis B virus infection in our
blood donors.
We bleed approximately 25,000 donors annually and
most of the blood units collected are from exchange
donors. Voluntary donations contribute to 11 % of the
above mentioned figure therefore discarding blood units
with elevated ALT in this situation results in its wastage.
A single collected unit is further processed into packed
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red cells, platelets and plasma. We found n = 207 blood
donors/units with markedly elevated ALT levels and discarding these units meant actually discarding 621 blood
products. The cost of performing ALT in 2006 was $3
while the cost of incinerating a blood product is $50.
Serological testing was $10 per bag. Therefore cost of
discarding these many donations was $ 39,123. We
found that ALT testing did not assist in identifying window period donations/occult hepatitis B infection. After
this study, we initiated Nucleic Acid Testing (NAT) of
our blood donors and ALT testing was discontinued.
Further large scale studies are warranted to explore
the association, if any between hepatitis B infection and
serum ALT. Our preliminary results showed no such
correlation between the two.
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